The risk of amenorrhea is related to chemotherapy-induced leucopenia in breast cancer patients receiving epirubicin and taxane based chemotherapy

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Zhou, Wenbin ^a   Ding, Qiang ^a   Liang, Xiuqing ^a   He, Zhongyuan ^a   Zha, Xiaoming ^a   Liu, Xiaoan ^a   Wang, Shui ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; LEUKOCYTE; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PREGNANCY; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME; ASIAN; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CHINA; MIDDLE AGED; PREMENOPAUSE; RETROSPECTIVE STUDY;

ADULT; AMENORRHEA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CHINA; EPIRUBICIN; FEMALE; HUMANS; LEUKOPENIA; MIDDLE AGED; PREMENOPAUSE; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 84861215850     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037249     Document Type: Article

References (33)

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) Lancet 365 (9472): 1687-1717.
2. Shapiro CL, Recht A, (2001) Side effects of adjuvant treatment of breast cancer. N Engl J Med 344 (26): 1997-2008.
3. Walshe JM, Denduluri N, Swain SM, (2006) Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 24 (36): 5769-5779.
4. Knobf MT, (2006) The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. Oncologist 11 (2): 96-110.
5. Perez-Fidalgo JA, Rosello S, Garcia-Garre E, Jorda E, Martin-Martorell P, et al. (2010) Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens. Breast Cancer Res Treat 120 (1): 245-251.
6. Swain SM, Land SR, Ritter MW, Costantino JP, Cecchini RS, et al. (2009) Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat 113 (2): 315-320.
7. Jeruss JS, Woodruff TK, (2009) Preservation of fertility in patients with cancer. N Engl J Med 360 (9): 902-911.
8. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, et al. (2006) American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24 (18): 2917-2931.
9. Di Cosimo S, Alimonti A, Ferretti G, Sperduti I, Carlini P, et al. (2004) Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol 15 (7): 1065-1071.
10. Han HS, Ro J, Lee KS, Nam BH, Seo JA, et al. (2009) Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat 115 (2): 335-342.
11. Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, et al. (2007) The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 30 (2): 126-132.
12. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, et al. (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352 (22): 2302-2313.
13. Najafi S, Djavid GE, Mehrdad N, Rajaii E, Alavi N, et al. (2011) Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea. Menopause 18 (2): 208-212.
14. Berliere M, Dalenc F, Malingret N, Vindevogel A, Piette P, et al. (2008) Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer 8: 56.
15. Zhou WB, Yin H, Liu XA, Zha XM, Chen L, et al. (2010) Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients. BMC Cancer 10: 281.
16. Amadori D, Silvestrini R, De Lena M, Boccardo F, Rocca A, et al. (2011) Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer. Breast Cancer Res Treat 125 (3): 775-784.
17. Margolin S, Bengtsson NO, Carlsson L, Edlund P, Hellstrom M, et al. (2011) A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. Acta Oncol 50 (1): 35-41.
18. Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, et al. (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 24 (36): 5664-5671.
19. Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I, (1997) Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75 (2): 301-305.
20. Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C, (1999) Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 80 (11): 1763-1766.
21. Mayers C, Panzarella T, Tannock IF, (2001) Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 91 (12): 2246-2257.
22. Cameron DA, Massie C, Kerr G, Leonard RC, (2003) Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 89 (10): 1837-1842.
23. Rosendahl M, Ahlgren J, Andersen J, Bergh J, Blomquist C, et al. (2009) The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: data from the randomised SBG 2000-1 study. Eur J Cancer 45 (18): 3198-3204.
24. Swain SM, Jeong JH, Geyer CE Jr, Costantino JP, Pajon ER, et al. (2010) Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362 (22): 2053-2065.
25. Sakurai K, Enomoto K, Amano S, (2011) Recovery of menstruation after long-term chemotherapy and endocrine therapy in pre-menopausal patients with breast cancer. J Cancer Res Clin Oncol 137 (4): 615-620.
26. Fornier MN, Modi S, Panageas KS, Norton L, Hudis C, (2005) Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 104 (8): 1575-1579.
27. Vanhuyse M, Fournier C, Bonneterre J, (2005) Chemotherapy-induced amenorrhea: influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients. Ann Oncol 16 (8): 1283-1288.
28. Minisini AM, Menis J, Valent F, Andreetta C, Alessi B, et al. (2009) Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era. Anticancer Drugs 20 (6): 503-507.
29. Blumenfeld Z, (2007) How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 12 (9): 1044-1054.
30. Knight PG, Glister C, (2006) TGF-beta superfamily members and ovarian follicle development. Reproduction 132 (2): 191-206.
31. Kitajima Y, Endo T, Nagasawa K, Manase K, Honnma H, et al. (2006) Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Endocrinology 147 (2): 694-699.
32. Rosendahl M, Andersen CY, la Cour Freiesleben N, Juul A, Løssl K, et al. (2010) Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. Fertil Steril 94 (1): 156-166.
33. Hulvat MC, Jeruss JS, (2009) Maintaining fertility in young women with breast cancer. Curr Treat Options Oncol 10 (5-6): 308-317.